Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RAB-202
- Development stage
- Preclinical
- Lead developer
- Zhongshan Laibo Ruichen Biopharmaceutical
- Modality
- Peptides
- Administration
- Subcutaneous, Local
01
Overview
RAB-202 is a long-acting peptide therapeutic being developed by ZhongShan LaiBo RuiChen BioMedicine (RabPharma) for the treatment of osteoporosis and to facilitate spinal fusion. As a long-acting peptide, it is designed for subcutaneous or local administration, potentially offering improved patient compliance or localized efficacy compared to standard peptide therapies. The drug is currently in the preclinical stage of development, focusing on bone and joint health. While its specific biological target has not been publicly disclosed, its development aligns with RabPharma's focus on innovative peptide-based treatments for bone and joint diseases.
Beyond the preview
Go deeper on RAB-202.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RAB-202.